Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Diabetes and Kidney Stones
4.2.2 Launch of Combination Drugs
4.3 Market Restraints
4.3.1 Adverse Effects Associated with the Use of Medication
4.3.2 Lack of Awareness in the Developing and Underdeveloped Countries
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 Drug
5.1.1 Penicillin and Combinations
5.1.2 Quinolones
5.1.3 Cephalosporin
5.1.4 Azoles and Amphotericin B
5.1.5 Nitrofurans
5.1.6 Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, etc.)
5.2 Indication
5.2.1 Complicated UTI
5.2.2 Uncomplicated UTI
5.2.3 Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Bayer AG
6.1.3 Cipla Inc.
6.1.4 GlaxoSmithKline PLC
6.1.5 Merlion Pharma
6.1.6 Novartis AG
6.1.7 Pfizer


7 MARKET OPPORTUNITIES AND FUTURE TRENDS